Showing results (1071-1080 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|April 12, 2012
Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cellsSheng Tai, Yin Sun, Nan Liu, et al.
Molecular Cancer Therapeutics|April 12, 2012
Overcoming platinum resistance through the use of a copper-lowering agentSiqing Fu, Aung Naing, Caroline Fu, et al.
Molecular Cancer Therapeutics|April 26, 2012
STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expressionShinji Kohsaka, Lei Wang, Kazuhiro Yachi, et al.
Molecular Cancer Therapeutics|April 26, 2012
Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link-generating agents in vitro and in vivoHui-Chun Wang, Alan Yueh-Luen Lee, Wen-Cheng Chou, et al.
Molecular Cancer Therapeutics|April 26, 2012
Inducible silencing of protein kinase D3 inhibits secretion of tumor-promoting factors in prostate cancerCourtney R LaValle, Liyong Zhang, Shuping Xu, et al.
Molecular Cancer Therapeutics|September 25, 2014
Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasisLe T Duong, Gregg A Wesolowski, Patrick Leung, et al.
Molecular Cancer Therapeutics|September 26, 2014
Coordinate hyperactivation of Notch1 and Ras/MAPK pathways correlates with poor patient survival: novel therapeutic strategy for aggressive breast cancersSuruchi Mittal, Ankur Sharma, Sai A Balaji, et al.
Molecular Cancer Therapeutics|September 26, 2014
CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathwayNaoya Saito, Keiichi Sakakibara, Takuji Sato, et al.
Molecular Cancer Therapeutics|September 26, 2014
SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancerDjango Sussman, Leia M Smith, Martha E Anderson, et al.
Molecular Cancer Therapeutics|September 26, 2014
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsPrasanth Ganesan, Stacy Moulder, J Jack Lee, et al.
Pageof 599